Multiple myeloma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BCMA 132
• CD38 22
• GPRC5D 35
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 4
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• AMPK 0
• B7-H3 0
• NRAS 1
• TIGIT 0
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 7,137 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

  NCT06876142· National Cancer Institute (NCI)· Updated 6 Nov 2026

  “Administrative hold pending non-safety related changes to the study design.”Registry text, quoted unchanged. Source

• Terminated

  Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

  NCT05996367· Instituto do Cancer do Estado de São Paulo· Updated 4 Nov 2026

  “Funding/ transfer PI”Registry text, quoted unchanged. Source

• Suspended

  CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

  NCT03710421· City of Hope Medical Center· Updated 30 Oct 2026

  “Slow/Low Accrual”Registry text, quoted unchanged. Source

• Terminated

  A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

  NCT04268199· AHS Cancer Control Alberta· Updated 28 Oct 2026

  “Operational limitations”Registry text, quoted unchanged. Source

• Suspended

  Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

  NCT06179888· National Cancer Institute (NCI)· Updated 19 Oct 2026

  “Scheduled Interim Monitoring”Registry text, quoted unchanged. Source

• Terminated

  64Cu-LLP2A for Imaging Hematologic Malignancies

  NCT06636175· Washington University School of Medicine· Updated 16 Oct 2026

  “Loss of further funding”Registry text, quoted unchanged. Source

• Suspended

  The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma

  NCT04300335· Medical University of Vienna· Updated 9 Oct 2026

  “The study was not started because the necessary resources could not yet be secured after COVID-19, which was the reason for the initial interruption of the study.”Registry text, quoted unchanged. Source

• Suspended

  External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

  NCT06572605· City of Hope Medical Center· Updated 7 Oct 2026

  “pending amendment”Registry text, quoted unchanged. Source

• Suspended

  Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

  NCT06232044· Alliance for Clinical Trials in Oncology· Updated 2 Oct 2026

  “Enrollment to Dose Level 1 cohort has been met”Registry text, quoted unchanged. Source

• Terminated

  First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

  NCT04401020· Sanofi· Updated 29 Sept 2026

  “Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511· Regeneron Pharmaceuticals· Source

• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

  NCT06876142· National Cancer Institute (NCI)· Source

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Regeneron Pharmaceuticals· Source

• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

  NCT06390852· National Cancer Institute (NCI)· Source

• Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  NCT07825064· Hoffmann-La Roche· Source

• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

  NCT05927571· Genentech, Inc.· Source

• A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Regeneron Pharmaceuticals· Source

• A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

  NCT05583617· Hoffmann-La Roche· Source

• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  NCT05137054· Regeneron Pharmaceuticals· Source

• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

  NCT06400238· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 16
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Measurable Residual Disease.

  Methods Mol Biol, Jan 2027

• Immunophenotyping of Human B Lymphocytes from Peripheral Blood Mononuclear Cells.

  Methods Mol Biol, Jan 2027

• Circulating tumor plasma cells correlate with tumor burden and routine laboratory markers in newly diagnosed multiple myeloma: A retrospective single-center study.

  Medicine (Baltimore), Oct 2026

• Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma.

  J Vis Exp, Aug 2026

• CD38+ T-Cell Count Is an Immunologic Phenotype Associated With Blood Pressure.

  Hypertension, Aug 2026

• Prospective Head-To-Head Comparison of a 10-Color Single-Tube Flow Cytometry and EuroFlow Next-Generation Flow in Multiple Myeloma Minimal Residual Disease.

  J Clin Lab Anal, Aug 2026

• [Construction and Validation of a Multivariable Nomogram Model for Survival Prediction in Patients with Multiple Myeloma].

  Zhongguo Shi Yan Xue Ye Xue Za Zhi, Aug 2026

• [Application of Multiparameter Flow Cytometry Combined with Serum Cys C and IL-10 in the Diagnosis of Multiple Myeloma].

  Zhongguo Shi Yan Xue Ye Xue Za Zhi, Aug 2026

• Therapy-Related Acute Lymphoblastic Leukemia with Plasmablastic Morphology after Myeloma: a Pitfall.

  Clin Lab, Aug 2026

• Baseline circulating tumor plasma cells are associated with progression-free survival in newly diagnosed multiple myeloma: a single-center real-world NGF study.

  Neoplasma, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.